Tag: information

CALGARY, Alberta, July 10, 2025 (GLOBE NEWSWIRE) -- News Release – TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) will hold a teleconference and webcast on Thursday, July 31, 2025, to discuss its second quarter financial results.

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified and premium cannabis, is pleased to announce that it will hold its Annual General and Special Meeting (the “Meeting”) of shareholders at 10:00 AM PT on July 31, 2025 in person at the Terminal City Club, 837 West Hastings Street, Vancouver, British Columbia, V6C 1B6, for the following purposes:

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Flutter Entertainment (NYSE: FLUT; LSE: FLTR) (“Flutter”) the world’s leading online sports betting and iGaming operator today announces the extension of its long-term strategic partnership with Boyd Gaming Corporation (“Boyd”) to 2038 and the buyout of Boyd’s 5% stake in FanDuel Group (“FanDuel”), together “the Agreement”.

New York, July 10, 2025 (GLOBE NEWSWIRE) -- Inception Growth Acquisition Limited (the “Company”), a blank check company, today announced that its previously announced special meeting of shareholders (the “Special Meeting”) will be postponed from 10:00 a.m. Hong Kong Time on July 14, 2025 to 10:00 a.m. Hong Kong Time on July 25, 2025 and accordingly, the deadline for stockholders to submit redemption requests will be extended to July 23, 2025.

SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the administration of the first dose of troculeucel, an expanded autologous NK cell therapy, under a single compassionate use, Investigational New Drug (“IND”) authorization cleared by the U.S. Food and Drug Administration (“FDA”), to a patient with mild-stage Alzheimer’s disease who exhibited continued cognitive decline despite ongoing treatment with lecanemab, an amyloid targeting therapy. This exploratory work is being conducted in collaboration with Anita Fletcher, M.D., a board-certified neurologist with specialized training in neuroimmunology, who also serves as Director of Neuroscience Clinical Research at AdventHealth Neuroscience Institute in Orlando, Florida.

PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- Clearway Energy, Inc. (NYSE: CWEN, CWEN.A) plans to report Second Quarter 2025 financial results on Tuesday, August 5, 2025. Management will present the results during a conference call and webcast at 5:00 p.m. Eastern.